Buch, Englisch, 288 Seiten, Format (B × H): 158 mm x 233 mm, Gewicht: 431 g
Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995
Buch, Englisch, 288 Seiten, Format (B × H): 158 mm x 233 mm, Gewicht: 431 g
ISBN: 978-0-521-62620-0
Verlag: Cambridge University Press
Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Geschichte der Medizin
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Wirtschaftswissenschaften Wirtschaftssektoren & Branchen Fertigungsindustrie Pharmaindustrie
Weitere Infos & Material
Preface; 1. 1894: 'The foremost medical question of the day'; 2. The Mulford story; 3. A Sharp & Dohme interlude; 4. The virology network and a new programme at Merck, Sharp & Dohme; 5. Hilleman's innovations: first phase, measles-mumps-rubella; 6. Dangerous interlude, Marek's Disease adjuvant 65, the Swine Flu drama; 7. Transforming bacteriology: a second phase, meningitis, pneumonia, haemophilus, influenzae; 8. New networks, new leadership: the Hepatitis B vaccines; 9. Vaccine innovation in the nineties: new strategies, new structures, and public confrontations; A word about sources.
